Drugs / Erythromycin
Erythromycin
also known as
Akne-mycin · Akne-Mycin- Egypt · Aknemycin plus · C-solve-2 · E-base · E-glades · E-mycin · E-solve 2 · +47 more
Small molecule targets CYP3A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ERYGEL | — | 1993-06-30 | fda.gov ↗ |
| Label expansion | US (FDA) | ILOTYCIN | — | 1967-05-03 | fda.gov ↗ |
| Approved | US (FDA) | ILOTYCIN | — | 1964-06-29 | fda.gov ↗ |
Trials 50
19621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047204820492050205120522053
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT06948747 | May → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06917872 | Apr → Sep 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07394725 | Apr 2024 → Mar 2025 | preterm premature rupture of the membranes | District Headquarters Teaching Hospital Sahiwal | Completed | No outcome recorded |
| Phase 1 | NCT06395610 | Mar → Jun 2024 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT05995249 | Aug → Dec 2023 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT04714554 | Jan → Mar 2021 | — | Myovant Sciences GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03480243 | Mar → Aug 2018 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT02381080 | May 2015 → Jun 2016 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01589614 | Jun → Aug 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01342198 | Jun → Jul 2011 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01323257 | Mar → Aug 2011 | chronic hepatitis C virus infection | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 1 | NCT01338441 | Mar → May 2011 | — | Ectycell SASU | Completed | No outcome recorded |
| Phase 1 | NCT01309438 | Feb 2011 → Mar 2012 | impaired renal function disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02755064 | Jun 2010 → Nov 2013 | type 1 diabetes mellitus | Adil Bharucha | Completed | No outcome recorded |
| Phase 1 | NCT00770042 | Oct → Nov 2008 | erectile dysfunction | VIVUS LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05579366 | Dec 2022 → Jul 2027 expected | breast adenocarcinoma, cervical cancer, endometrial cancer, fallopian tube cancer +5 | Genmab | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00467831 | Apr 2007 → Nov 2012 | Hermansky-Pudlak syndrome, oculocutaneous albinism, platelet storage pool deficiency, pulmonary fibrosis | National Human Genome Research Institute (NHGRI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT01659619 | Apr → Oct 2012 | gastric cancer | The Catholic University of Korea | Completed | Met primary |
| Phase 2 | NCT01668498 | May 2011 → Jan 2015 | colorectal cancer | AIO-Studien-gGmbH | Completed | No outcome recorded |
| Phase 2 | NCT00304187 | Sep 2004 → Nov 2011 | bulimia nervosa | New York State Psychiatric Institute | Completed | Met primary |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT00147667 | Apr 2004 → Mar 2006 | chronic obstructive pulmonary disease | Royal Free and University College Medical School | Unknown | Met primary |
| Phase 35 trials · 2 missed | ||||||
| Phase 3 | NCT01340235 | Jun → Dec 2011 | epidermolysis bullosa | Centre Hospitalier Universitaire de Nice | Unknown | No outcome recorded |
| Phase 3 | NCT00718315 | Apr 2009 → Jun 2012 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT00259220 | Dec 2005 → Aug 2008 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00000120 | Jan 1985 → ? | chlamydia trachomatis infectious disease, ophthalmia neonatorum | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 3 | NCT00021671 | ? → Nov 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 410 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT06396078 | Jul 2024 → Dec 2026 expected | preterm premature rupture of the membranes | Ohio State University | Recruiting | No outcome recorded |
| Phase 4 | NCT03883269 | Mar 2018 → Jun 2019 overdue | acne | Centre for Human Drug Research, Netherlands | Recruiting | No outcome recorded |
| Phase 4 | NCT03199911 | Oct 2017 → Nov 2019 | drug allergy, eyelid disorder, poisoning, skin cancer | University of California, San Francisco | Completed | Met primary |
| Phase 4 | NCT02354560 | Jun 2015 → Dec 2017 | classic familial adenomatous polyposis | michal roll | Unknown | No outcome recorded |
| Phase 4 | NCT02212821 | Sep 2014 → Sep 2016 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 4 | NCT02175914 | Jun 2014 → Jun 2015 | classic familial adenomatous polyposis | michal roll | Unknown | No outcome recorded |
| Phase 4 | NCT00318201 | Apr 2006 → Dec 2007 | — | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00999232 | Oct 2004 → Jul 2007 | pancreatitis | Canisius-Wilhelmina Hospital | Completed | Missed primary |
| Phase 4 | NCT00367419 | — | toxic bronchiolitis obliterans | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
| Phase 4 | NCT00368342 | — | asthma | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT06461429 | Nov 2025 → Dec 2050 expected | — | University of Melbourne | Not yet recruiting | No outcome recorded |
| — | NCT05328817 | May 2022 → May 2025 | preterm premature rupture of the membranes | Eastern Virginia Medical School | Unknown | No outcome recorded |
| — | NCT05290753 | Jan → Jun 2022 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT04066231 | Sep 2019 → Mar 2020 | intestinal dysmotility syndrome | Prof Dr Jan Tack | Terminated | No outcome recorded |
| — | NCT03966066 | Aug 2019 → Jul 2020 | bronchiectasis | Beijing Children's Hospital | Unknown | No outcome recorded |
| — | NCT03779360 | Oct 2018 → Feb 2019 | dermatitis | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
| — | NCT03436719 | Nov 2017 → Jul 2020 | rectal cancer | State Scientific Centre of Coloproctology, Russian Federation | Unknown | No outcome recorded |
| — | NCT02528760 | Sep 2015 → Aug 2017 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT02017379 | Jun → Sep 2014 | — | Texas Tech University Health Sciences Center, El Paso | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT02005029 | Apr 2013 → Jun 2015 | Parkinson disease, autosomal dominant dopa-responsive dystonia | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT02622802 | Nov 2012 → Dec 2016 | pregnancy disorder | University Hospital, Gasthuisberg | Completed | No outcome recorded |
| — | NCT01825473 | Sep 2012 → Mar 2014 | apnea of prematurity, gastroesophageal reflux disease | University of Virginia | Unknown | No outcome recorded |
| — | NCT00589329 | Dec 2007 → Oct 2012 | — | MetroHealth Medical Center | Terminated | No outcome recorded |
| — | NCT00373919 | — | esophageal disorder | Kaplan Medical Center | Unknown | No outcome recorded |
| Comparator or background therapy31 trials | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02251132 Background | Oct → Dec 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00002194 Background | — | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT06858618 Background | Aug 2023 → Dec 2026 expected | — | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01946256 Comparator | Oct 2013 → Mar 2014 | chlamydia trachomatis infectious disease | Obafemi Awolowo University Teaching Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01117376 Comparator | May 2010 → Jun 2011 | gastroparesis | Shiraz University of Medical Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT01323582 Comparator | Feb 2009 → Dec 2012 | gastroparesis | University of Florida | Terminated | Missed primary |
| Phase 2 | NCT00827216 Comparator | Jan 2009 → Apr 2013 | aspiration pneumonia | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 2/3 | NCT02605122 Comparator | Apr 2016 → Mar 2018 | bacterial pneumonia | Melinta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT01379183 Comparator | Jun 2011 → Mar 2012 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT06273891 Comparator | Mar 2024 → May 2026 overdue | preterm premature rupture of the membranes | Inova Health Care Services | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03060473 Comparator | Feb 2017 → Dec 2023 | preterm premature rupture of the membranes | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 3 | NCT01716572 Comparator | Feb 2012 → Sep 2015 | — | Hospital Universitari de Bellvitge | Unknown | No outcome recorded |
| Phase 3 | NCT01556334 Comparator | Apr 2010 → Oct 2012 | preterm premature rupture of the membranes | Indiana University | Withdrawn | No outcome recorded |
| Phase 3 | NCT01401179 Comparator | Apr 2005 → Apr 2010 | preterm premature rupture of the membranes | Samsung Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00648726 Comparator | Jan → Aug 2003 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT03024879 Comparator | Mar 2014 → Mar 2025 overdue | obesity disorder | Universitaire Ziekenhuizen KU Leuven | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT01478256 Comparator | Aug → Oct 2011 | blepharitis | John, George, M.D. | Completed | No outcome recorded |
| — | NCT06906757 Comparator | Sep 2025 → Dec 2029 expected | preterm premature rupture of the membranes | University of Melbourne | Not yet recruiting | No outcome recorded |
| — | NCT07063082 Comparator | Jul → Sep 2025 overdue | chronic rhinosinusitis | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT04665089 Comparator | Jan 2022 → Jan 2023 | infectious disease with sepsis | Tunis University | Completed | No outcome recorded |
| — | NCT04682691 Comparator | Mar 2021 → Feb 2024 | — | Cairo University | Completed | No outcome recorded |
| — | NCT04254601 Background | Apr 2018 → Jun 2019 | skin disorder | Cairo University | Completed | No outcome recorded |
| — | NCT03473210 Comparator | Oct 2016 → Dec 2017 | preterm premature rupture of the membranes | Cairo University | Completed | No outcome recorded |
| — | NCT02515565 Background | Sep 2015 → Apr 2018 | pneumonia | University of Granada | Unknown | No outcome recorded |
| — | NCT02481219 Background | May 2015 → Jan 2016 | colorectal cancer | Medtronic - MITG | Completed | No outcome recorded |
| — | NCT02362906 Background | Apr 2014 → Aug 2015 | pneumonia | Liaoning University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT02633579 Comparator | Oct 2012 → Aug 2014 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT01569633 Comparator | Oct 2011 → Feb 2014 | nutritional disorder, pulmonary immaturity | East Tennessee State University | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01097811 Comparator | Jun 2008 → Jun 2010 | cirrhosis of liver, hepatic encephalopathy, portal hypertension | UPECLIN HC FM Botucatu Unesp | Unknown | No outcome recorded |
| — | NCT01060267 Comparator | Jan 2007 → May 2009 | esophageal varices with bleeding | King Abdulaziz Medical City | Completed | No outcome recorded |
Evidence & citations 60 cited values
Every value below carries the sentence it was read from. 82 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Erythromycin | “Receive 1) erythromycin 250 mg iv every 6 hours for 48 hours followed by 333 mg orally (pills) every 8 hours for 5 days” NCT05328817 ↗80“Metronidazole - 500 mg and Erythromycin - 500 mg per os *3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery” NCT03436719 ↗ “ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days” NCT03473210 ↗ “Topical antibiotic ointment will be erythromycin or bacitracin.” NCT03199911 ↗ “Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)” NCT00770042 ↗ “Azithromycin or erythromycin may be added as well.” NCT02605122 ↗ “use of erythromycin IV before endoscopy” NCT00259220 ↗ “Primpiram and gastreg and erythromycin” NCT05290753 ↗ “Erythromycin” NCT02099240 ↗ |
| Known as | Akne-mycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Akne-Mycin- Egypt | “topical erythromycin cream 2% (Akne-Mycin- Egypt) two times per day on the entire face from the beginning to the end of the treatment period” NCT04254601 ↗ |
| Known as | Aknemycin plus | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | C-solve-2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | E-base | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | E-glades | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | E-mycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | E-solve 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Emgel | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Eritex | “erythromycin [Eritex]” NCT00718315 ↗ |
| Known as | Eritromicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Ery-tab | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Eryacne 2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Eryacne 4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Eryc | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Eryc 125 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Eryc sprinkles | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erycette | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Eryderm | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erygel | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erymax | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erymax sprinkle | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythra-derm | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythro 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythro-statin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythrocin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythrocin 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythrocin acne pack | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythrocine | “The administration of the drug, 40 mg of the motilin receptor agonist erythromycin lactobionate (Erythrocine; Abbott, Ottignies-Louvain-la-Neuve, Belgium), will be given in a...” NCT02633579 ↗ |
| Known as | Erythromycin component of aktipak | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythromycin component of benzamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Erythromycin estolate impurity, free erythromycin- | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | erythromycin lactobionate | “The administration of the drug, 40 mg of the motilin receptor agonist erythromycin lactobionate (Erythrocine; Abbott, Ottignies-Louvain-la-Neuve, Belgium), will be given in a...” NCT02633579 ↗ |
| Known as | Erythromycini lactobionas | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Ethril 250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Ethril 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Ilotycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Ilotycin gluceptate | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Isotrexin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | J01FA01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Kerymax | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | NSC-55929 | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Oftalmolosa cusi eritromicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Pce (erythromycin) | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | R-p mycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Retcin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Robimycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Rommix 250 ec | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Rommix 500 ec | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Sansac | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Staticin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Sterile erythromycin lactobionate | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Stiemycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | T-stat | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Known as | Zineryt | ChEMBL registry synonym — accepted as the source's own label CHEMBL532 ↗ |
| Action | Activate | “This motilin receptor agonist” NCT00259220 ↗ |
| Modality | Small molecule | “Macrolides such as erythromycin have been shown to have potent anti-inflammatory effects” NCT00147667 ↗ |
| Route | Intravenous | “Patients in Group II receive erythromycin intravenously on days 0, 14, 28, and 43” NCT00002194 ↗ |
| Target | CYP3A4 | “erythromycin is a moderate CYP3A4 inhibitor” NCT00770042 ↗ |